Innovative Bispecific Nanobody Therapy Targeting CD3 Complex and IL13RA2 for Cancer Immunotherapy
VHH-P527 is a humanized bispecific nanobody currently in the Biological Testing stage, developed for the potential treatment of cancer. This novel biologic simultaneously targets the CD3 Complex (T Cell Receptor Complex), a key mediator of T-cell activation, and interleukin 13 receptor subunit alpha 2 (IL13RA2), often overexpressed in a variety of malignancies. By harnessing these well-validated molecular targets, VHH-P527 is designed to bridge immune effector cells and tumor-specific antigens, aiming to initiate a potent and selective anti-tumor immune response. Its advanced molecular design holds the promise of addressing critical challenges in cancer therapy.
| Candidate | VHH-P527 |
| Target | CD3 Complex (T Cell Receptor Complex) interleukin 13 receptor subunit alpha 2 (IL13RA2) |
| Modality | humanized bispecific VHH |
| Indication | Cancer |
Licensing Opportunity
VHH-P527 is available for out-licensing to partners interested in advancing innovative immunotherapy for cancer. Collaboration and co-development opportunities are welcomed to accelerate clinical and commercial success.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P527 |
Modality
VHH-P527 is a bispecific antibody composed of two humanized single-domain antibodies specifically binding to IL13RA2, fused to a variable fragment targeting CD3 and an engineered Fc domain for optimized developability. The nanobody structure confers a small molecular size and high stability, enabling superior tumor tissue penetration compared to conventional antibodies. The modularity and humanization of this format reduce immunogenic risks while retaining robust binding specificity and manufacturability. These attributes make VHH-P527 particularly advantageous for the treatment of cancer, where deep tissue access and engagement of immune effectors are crucial for therapeutic success.
Target
CD3 Complex is a multimeric protein complex expressed on the surface of T lymphocytes and is essential for antigen recognition and T-cell activation, making it a strategic immunotherapy target. IL13RA2 is a transmembrane protein frequently overexpressed in numerous cancer types, where it contributes to tumor progression and immune evasion. While CD3 Complex is primarily found on T cells within the immune system, IL13RA2 displays selective expression on malignant cells but limited expression in normal tissues. Targeting CD3 Complex enables redirection of T cells, while engagement of IL13RA2 confers tumor specificity. VHH-P527’s concurrent targeting of CD3 Complex and IL13RA2 embodies a rational design innovation, maximizing therapeutic selectivity and minimizing off-tumor activation. This dual engagement strategy represents a significant strategic value for oncology therapeutics.
Mechanism of Action
VHH-P527 functions as a T-cell engager, simultaneously binding to CD3 Complex on T cells and IL13RA2 on tumor cells. Through these interactions, VHH-P527 modulates signal transduction to facilitate targeted recruitment and activation of cytotoxic T lymphocytes at the tumor site, resulting in selective cancer cell killing. The nanobody-based bispecific scaffold additionally benefits from high tissue penetrance and versatile molecular engineering, opening opportunities for adaptation into antibody-drug conjugates (ADC) or further multispecific platforms. The mechanism is designed to merge immune redirection with tumor specificity, offering a promising approach to overcome resistance and achieve durable responses in cancer therapy.
Cancer
Cancer represents a highly heterogeneous group of diseases characterized by uncontrolled cell proliferation and the ability to invade or spread to distant organs. It remains a leading cause of morbidity and mortality worldwide, affecting millions of individuals across all demographics. Current standard treatments include surgery, radiotherapy, chemotherapy, and targeted therapies such as monoclonal antibodies and immune checkpoint modulators. While progress has been made, major limitations persist, including non-specific toxicity, limited efficacy in refractory cases, and resistance to existing therapies. There is a substantial unmet medical need for novel agents that combine specific tumor targeting with potent immunomodulatory effects. VHH-P527 is positioned to address these gaps by integrating precise immune cell engagement with selective tumor antigen recognition, thereby offering the potential for enhanced safety and efficacy compared to traditional modalities.